You either didn't read or didn't understand the decision. They are the same, interchangeable vaccine. The only distinction is approval status, and that some batches were manufactured at facilities not approved in the BLA, so those continue to have to be labeled for EUA use only.
This is what the judge actually ruled:
In short, what people think of as the Pfizer vaccine has two distinct FDA approval statuses. It is licensed—that is, fully approved—for the two-dose application in those 16 and older.* But it is unlicensed and operating under an EUA— that is, an emergency use authorization—for other applications, like for children under 16 and for certain third shots.** Nonetheless, the FDA describes the two as the “same formulation” and “interchangeabl[e]” for medical purposes. See ECF No. 1- 6 at 3 n.8.5
asterisks mine
*in this situation, it is called by its brand name, Cominarty. Drug companies cannot use a brand name for a drug until it receives FDA approval. The vaccine, as administered for the two dose application in 16 and older, is Cominarty, regardless of the color of the cap on the vial or the label itself.
**in this situation, it is called by the EUA name, Pfizer-BioNTech COVID-19 Vaccine. The vaccines are one and the same. The only difference is the label and the color of the cap on the vial.